The membrane complement regulatory protein CD59 promotes tumor growth and predicts poor prognosis in breast cancer

Ouyang,Qianwen; Zhang,Long; Jiang,Yizhou; Ni,Xiaojian; Chen,Sheng; Ye,Fugui; Du,Yiqun; Huang,Liang; Ding,Peipei; Wang,Na; Yang,Chaoqun; Huang,Tianbao; Sun,Yujing; Li,Shan; Xia,Yun; Hu,Weiguo; Luo,Rongcheng; Shao,Zhiming

doi:10.3892/ijo.2016.3408

The membrane complement regulatory protein CD59 promotes tumor growth and predicts poor prognosis in breast cancer

Authors:
- Qianwen Ouyang
- Long Zhang
- Yizhou Jiang
- Xiaojian Ni
- Sheng Chen
- Fugui Ye
- Yiqun Du
- Liang Huang
- Peipei Ding
- Na Wang
- Chaoqun Yang
- Tianbao Huang
- Yujing Sun
- Shan Li
- Yun Xia
- Weiguo Hu
- Rongcheng Luo
- Zhiming Shao
View Affiliations

Affiliations: Department of Breast Surgery, The Third Hospital of Nanchang, China Jiangxi Province Key Laboratory for Breast Diseases, Nanchang, Jiangxi, P.R. China, Fudan University Cancer Institute, Shanghai Cancer Center, Shanghai, P.R. China, Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Shanghai Cancer Center, Fudan University, Shanghai, P.R. China, Department of General Surgery, Affiliated Union Hospital of Fujian Medical University, Union Clinical School, Fujian Medical University, Fujian, P.R. China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China, Department of Hand Surgery, Huashan Hospital, Fudan University, Shanghai, P.R. China, Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, P.R. China, Cancer Center, Traditional Chinese Medicine-Integrated Hospital, Southern Medical University, Guangzhou, Guangdong, P.R. China
Published online on: February 24, 2016 https://doi.org/10.3892/ijo.2016.3408
Pages: 2015-2024

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer is the most prevalent type of cancer among women. CD59, a membrane complement regulatory protein, has been demonstrated to be overexpressed in most solid tumors, where it facilitates tumor cell escape from complement surveillance. However, the role of CD59 in breast cancer growth and clinical prognosis is not fully revealed. To investigate the role of CD59 in breast cancer growth and prognostic significance, we knocked down CD59 in a breast cancer cell line that is highly metastatic to the lungs, MDA-MB‑231-HM. Cell growth was measured in vitro and in vivo using a xenograft model. In addition, clinical data on a cohort of 120 patients with or without lung metastasis was analyzed based on CD59 expression, which was detected by immunohistochemistry. Knockdown of CD59 significantly inhibited MDA-MB‑231-HM cell growth both in vitro and in vivo. An analysis of clinical data on 120 patients revealed that patients with CD59 overexpression may have a worse prognosis. CD59 may therefore be a prognostic biomarker for poor outcome in breast cancer patients.

View Figures

View References

1	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
2	Elmore JG, Armstrong K, Lehman CD and Fletcher SW: Screening for breast cancer. JAMA. 293:1245–1256. 2005. View Article : Google Scholar : PubMed/NCBI
3	Tabár L, Vitak B, Chen HH, Duffy SW, Yen MF, Chiang CF, Krusemo UB, Tot T and Smith RA: The Swedish Two-County Trial twenty years later. Updated mortality results and new insights from long-term follow-up. Radiol Clin North Am. 38:625–651. 2000. View Article : Google Scholar : PubMed/NCBI
4	Soerjomataram I, Louwman MW, Ribot JG, Roukema JA and Coebergh JW: An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat. 107:309–330. 2008. View Article : Google Scholar :
5	Foulkes WD, Reis-Filho JS and Narod SA: Tumor size and survival in breast cancer - a reappraisal. Nat Rev Clin Oncol. 7:348–353. 2010. View Article : Google Scholar : PubMed/NCBI
6	Anan K, Mitsuyama S, Koga K, Tanabe R, Saimura M, Tanabe Y, Watanabe M, Suehara N, Matsunaga H, Nishihara K, et al: Disparities in the survival improvement of recurrent breast cancer. Breast Cancer. 17:48–55. 2010. View Article : Google Scholar
7	Nguyen DX, Bos PD and Massagué J: Metastasis: From dissemination to organ-specific colonization. Nat Rev Cancer. 9:274–284. 2009. View Article : Google Scholar : PubMed/NCBI
8	Chaffer CL and Weinberg RA: A perspective on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
9	Morgan BP, Marchbank KJ, Longhi MP, Harris CL and Gallimore AM: Complement: Central to innate immunity and bridging to adaptive responses. Immunol Lett. 97:171–179. 2005. View Article : Google Scholar : PubMed/NCBI
10	Ricklin D, Hajishengallis G, Yang K and Lambris JD: Complement: A key system for immune surveillance and homeo-stasis. Nat Immunol. 11:785–797. 2010. View Article : Google Scholar : PubMed/NCBI
11	Matsumoto M, Takeda J, Inoue N, Hara T, Hatanaka M, Takahashi K, Nagasawa S, Akedo H and Seya T: A novel protein that participates in nonself discrimination of malignant cells by homologous complement. Nat Med. 3:1266–1270. 1997. View Article : Google Scholar : PubMed/NCBI
12	Dunkelberger JR and Song WC: Complement and its role in innate and adaptive immune responses. Cell Res. 20:34–50. 2010. View Article : Google Scholar
13	Zhou X, Hu W and Qin X: The role of complement in the mechanism of action of rituximab for B-cell lymphoma: Implications for therapy. Oncologist. 13:954–966. 2008. View Article : Google Scholar : PubMed/NCBI
14	Fishelson Z, Donin N, Zell S, Schultz S and Kirschfink M: Obstacles to cancer immunotherapy: Expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol. 40:109–123. 2003. View Article : Google Scholar : PubMed/NCBI
15	Davies A and Lachmann PJ: Membrane defence against complement lysis: The structure and biological properties of CD59. Immunol Res. 12:258–275. 1993. View Article : Google Scholar : PubMed/NCBI
16	Li B, Lin H, Fan J, Lan J, Zhong Y, Yang Y, Li H and Wang Z: CD59 is overexpressed in human lung cancer and regulates apoptosis of human lung cancer cells. Int J Oncol. 43:850–858. 2013.PubMed/NCBI
17	Hu W, Ge X, You T, Xu T, Zhang J, Wu G, Peng Z, Chorev M, Aktas BH, Halperin JA, et al: Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis. Cancer Res. 71:2298–2307. 2011. View Article : Google Scholar : PubMed/NCBI
18	Rus HG, Niculescu FI and Shin ML: Role of the C5b-9 complement complex in cell cycle and apoptosis. Immunol Rev. 180:49–55. 2001. View Article : Google Scholar : PubMed/NCBI
19	Madjd Z, Pinder SE, Paish C, Ellis IO, Carmichael J and Durrant LG: Loss of CD59 expression in breast tumours correlates with poor survival. J Pathol. 200:633–639. 2003. View Article : Google Scholar : PubMed/NCBI
20	Li B, Chu X, Gao M and Xu Y: The effects of CD59 gene as a target gene on breast cancer cells. Cell Immunol. 272:61–70. 2011. View Article : Google Scholar : PubMed/NCBI
21	Terp MG, Lund RR, Jensen ON, Leth-Larsen R and Ditzel HJ: Identification of markers associated with highly aggressive meta-static phenotypes using quantitative comparative proteomics. Cancer Genomics Proteomics. 9:265–273. 2012.PubMed/NCBI
22	Maio M, Brasoveanu LI, Coral S, Sigalotti L, Lamaj E, Gasparollo A, Visintin A, Altomonte M and Fonsatti E: Structure, distribution, and functional role of protectin (CD59) in complement-susceptibility and in immunotherapy of human malignancies (Review). Int J Oncol. 13:305–318. 1998.PubMed/NCBI
23	Liu ZB, Hou YF, Min-Dong, Di GH, Wu J, Shen ZZ and Shao ZM: PA-MSHA inhibits proliferation and induces apoptosis through the up-regulation and activation of caspases in the human breast cancer cell lines. J Cell Biochem. 108:195–206. 2009. View Article : Google Scholar : PubMed/NCBI
24	Du Y, Teng X, Wang N, Zhang X, Chen J, Ding P, Qiao Q, Wang Q, Zhang L, Yang C, et al: NF-κB and enhancer-binding CREB protein scaffolded by CREB-binding protein (CBP)/p300 proteins regulate CD59 protein expression to protect cells from complement attack. J Biol Chem. 289:2711–2724. 2014. View Article : Google Scholar :
25	Detre S, Saclani Jotti G and Dowsett M: A ‘quickscore’ method for immunohistochemical semiquantitation: Validation for oestrogen receptor in breast carcinomas. J Clin Pathol. 48:876–878. 1995. View Article : Google Scholar : PubMed/NCBI
26	Harvey JM, Clark GM, Osborne CK and Allred DC: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 17:1474–1481. 1999.PubMed/NCBI
27	Du K and Montminy M: CREB is a regulatory target for the protein kinase Akt/PKB. J Biol Chem. 273:32377–32379. 1998. View Article : Google Scholar : PubMed/NCBI
28	Choi YH, Lee SN, Aoyagi H, Yamasaki Y, Yoo JY, Park B, Shin DM, Yoon HG and Yoon JH: The extracellular signal-regulated kinase mitogen-activated protein kinase/ribosomal S6 protein kinase 1 cascade phosphorylates cAMP response element-binding protein to induce MUC5B gene expression via D-prostanoid receptor signaling. J Biol Chem. 286:34199–34214. 2011. View Article : Google Scholar : PubMed/NCBI
29	Boulware MI, Weick JP, Becklund BR, Kuo SP, Groth RD and Mermelstein PG: Estradiol activates group I and II metabotropic glutamate receptor signaling, leading to opposing influences on cAMP response element-binding protein. J Neurosci. 25:5066–5078. 2005. View Article : Google Scholar : PubMed/NCBI
30	Liu M, Yang YJ, Zheng H, Zhong XR, Wang Y, Wang Z, Wang YG and Wang YP: Membrane-bound complement regulatory proteins are prognostic factors of operable breast cancer treated with adjuvant trastuzumab: A retrospective study. Oncol Rep. 32:2619–2627. 2014.PubMed/NCBI
31	Mamidi S, Cinci M, Hasmann M, Fehring V and Kirschfink M: Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab. Mol Oncol. 7:580–594. 2013. View Article : Google Scholar : PubMed/NCBI
32	Samatar AA and Poulikakos PI: Targeting RAS-ERK signalling in cancer: Promises and challenges. Nat Rev Drug Discov. 13:928–942. 2014. View Article : Google Scholar : PubMed/NCBI
33	Lipp AM, Juhasz K, Paar C, Ogris C, Eckerstorfer P, Thuenauer R, Hesse J, Nimmervoll B, Stockinger H, Schütz GJ, et al: Lck mediates signal transmission from CD59 to the TCR/CD3 pathway in Jurkat T cells. PLoS One. 9:e859342014. View Article : Google Scholar : PubMed/NCBI